ArticleInternational journal of reproductive biomedicine2026
Serum amyloid A as a diagnostic marker for histologic chorioamnionitis in preterm premature rupture of membranes: A diagnostic accuracy study.
Article in International journal of reproductive biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chorioamnionitis is an acute inflammation of the fetal membrane in mothers with preterm premature rupture of the membrane (PPROM). The diagnosis of chorioamnionitis is based on clinical findings; however, laboratory tests may help diagnose the disease. Objective: It aimed to evaluate the accuracy of maternal serum-amyloid A (SAA) protein levels in diagnosing histopathologic chorioamnionitis following PPROM mothers; secondarily, it assessed their accuracy for diagnosing clinical chorioamnionitis. Materials and Methods: In this diagnostic accuracy study, 94 PPROM pregnancies, referred to Namazi, Hafez, and Zeinabiyeh hospitals, Shiraz, Iran, from March 2022 to March 2023 were followed. All placentas were examined for histopathological evidence of chorioamnionitis, and participants were classified into 2 pathologic chorioamnionitis and normal placenta groups. Results: From the 94 participants, 50 (43.20%) were pathologically diagnosed with chorioamnionitis as pathologic chorioamnionitis group, and the remaining 44 (46.80%) belonged to control "normal placenta group". In addition, 50% (25/50) of women with pathological chorioamnionitis were clinically diagnosed with chorioamnionitis as clinic chorioamnionitis group, and the remaining 50% (25/50) with no clinical signs of chorioamnionitis belonged to their control. Pathologic at-delivery SAA were more in the pathologic chorioamnionitis group compared with normal placenta group; adjusted odds ratio (95% confidence interval); 15.20 (2.62-88.20); the area under curve values (cutoff point, sensitivity, specificity, negative predictive value, positive predictive value, and accuracy) were 0.83 ( Conclusion: Pathologic at-delivery SAA level could be a supplementary test in PPROM mothers. At-delivery SAA serial measurements and long-term evaluation of infants born to these mothers are recommended.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.